- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
Because every stock has a unique personality that requires its own strategy.